Sepracor discontinues Soltara
Executive Summary
Sepracor discontinues development of allergic rhinitis treatment Soltara (tecastemizole). FDA issued "not approvable" letter in March 2002, citing insufficient evidence concerning QTc interval prolongation (1"The Pink Sheet" March, 11, 2002, In Brief)...